Radiopharm Theranostics Ltd - Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value (RADX) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2024 to Q3 2025

Type / Class
Equity / Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value
Symbol
RADX on Nasdaq
Shares outstanding
3,543,587,624
Price per share
$5.16
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
312,506
Total reported value
$1,725,033
% of total 13F portfolios
0%
Share change
-27,184
Value change
-$119,409
Number of holders
4
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Radiopharm Theranostics Ltd - Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value (RADX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
REGAL PARTNERS HOLDINGS PTY LTD 9% +25% $1,362,952,390 +$629,253,691 320,694,680 +86% Regal Partners Holdings Pty Limited 31 Dec 2025

As of 30 Sep 2025, 4 institutional investors reported holding 312,506 shares of Radiopharm Theranostics Ltd - Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value (RADX). This represents 0.01% of the company’s total 3,543,587,624 outstanding shares.

Institutional Holders of Radiopharm Theranostics Ltd - Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value (RADX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 312,506 $1,725,033 -$119,409 $5.52 4
2025 Q2 339,690 $1,576,875 -$15,543 $4.64 5
2025 Q1 342,915 $1,649,421 -$446,370 $4.81 3
2024 Q4 435,803 $1,939,576 +$1,939,576 $4.49 4